The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Official Title: A Phase 3b, Multicenter, Single-arm, Expanded Access Protocol of Tarlatamab (AMG 757) for the Treatment of Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Study ID: NCT06064500
Brief Summary: The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Yale School of Medicine, New Haven, Connecticut, United States
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Martin Memorial Health System, Stuart, Florida, United States
Nebraska Cancer Specialists, Omaha, Nebraska, United States
Perlmutter Cancer Center at New York University Langone Hospital - 34th Street, New York, New York, United States
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
University of Virginia, Charlottesville, Virginia, United States
Cancer Care Northwest - South, Spokane, Washington, United States
Associacao Hospitalar Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil
Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Sao Paulo, São Paulo, Brazil
Okayama University Hospital, Okayama-shi, Okayama, Japan
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR